Market research
PLXP PLx Pharma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- 0.0%
- Beta
- 3.92
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- US72942A1079
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- 0.0%
- Beta
- 3.92
About
About PLx Pharma Inc
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. On April 13, 2023, PLx Pharma Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PLXP discussion.
5 years, 4 months ago
PLx Pharma Inc is currently in a long term uptrend where the price is trading 60.0% above its 200 day moving average.
From a valuation standpoint, the stock is 117.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2908.4.
PLx Pharma Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 299.1% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.5% to $-3M since the same quarter in the previous year.
Based on the above factors, PLx Pharma Inc gets an overall score of 2/5.